Insulet Co. (NASDAQ:PODD) Shares Bought by Huntington National Bank

Huntington National Bank grew its position in Insulet Co. (NASDAQ:PODD) by 27.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 907 shares of the medical instruments supplier’s stock after acquiring an additional 196 shares during the quarter. Huntington National Bank’s holdings in Insulet were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. SBI Securities Co. Ltd. purchased a new stake in Insulet in the 4th quarter valued at $36,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the period. Friedenthal Financial purchased a new position in shares of Insulet during the fourth quarter worth about $57,000. Finally, Assetmark Inc. increased its position in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares during the period.

Insulet Trading Down 4.5 %

NASDAQ PODD opened at $245.26 on Friday. The company has a market cap of $17.22 billion, a P/E ratio of 42.36, a P/E/G ratio of 3.62 and a beta of 1.30. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a 50-day moving average of $269.86 and a 200-day moving average of $259.70.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. TD Cowen upped their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. lifted their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Stifel Nicolaus increased their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Finally, Raymond James reaffirmed an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.